Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$44.71 USD
-0.68 (-1.50%)
Updated May 17, 2024 04:00 PM ET
After-Market: $44.74 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 21 - 40 ( 184 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for HALO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Win for Enhanze-Vyvgart SC Approved in EU; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Growth in Quarter; 3Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Earnings Preview; Enhanze Partnerships Driving Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Subcutaneous Opdivo Notches Win; Approval Risk-Mitigated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Darzalex Revenues Continue to Grow; Raising PT to $61
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Auto-Injector Data Suggest Rapid Large Payload Delivery; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tlando Rights Returned; We Expect No Material Impact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Tecentriq SC U.S. Launch; We Expect Approval Next Week; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Great Britain Tecentriq SC Approval Mitigates FDA, EMA Risk; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M